Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
Michishige Terasaki, Masaharu Nagashima, Kyoko Nohtomi, et al.
PLoS ONE (2013) Vol. 8, Iss. 8, pp. e70933-e70933
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Mechanisms of foam cell formation in atherosclerosis
Dimitry A. Chistiakov, Alexandra А. Melnichenko, Veronika A. Myasoedova, et al.
Journal of Molecular Medicine (2017) Vol. 95, Iss. 11, pp. 1153-1165
Closed Access | Times Cited: 578
Macrophage‐mediated cholesterol handling in atherosclerosis
Dimitry A. Chistiakov, Yuri V. Bobryshev, Alexander N. Orekhov
Journal of Cellular and Molecular Medicine (2015) Vol. 20, Iss. 1, pp. 17-28
Open Access | Times Cited: 444
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis
Yannick Waumans, Lesley Baerts, Kaat Kehoe, et al.
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 179
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
DPP4 in Cardiometabolic Disease
Jixin Zhong, Andrei Maiseyeu, Stephen N. Davis, et al.
Circulation Research (2015) Vol. 116, Iss. 8, pp. 1491-1504
Open Access | Times Cited: 166
A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
Yuko Tashiro, Kengo Sato, Takuya Watanabe, et al.
Peptides (2014) Vol. 54, pp. 19-26
Closed Access | Times Cited: 128
DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway
Yao Dai, Dongsheng Dai, Xianwei Wang, et al.
Cardiovascular Drugs and Therapy (2014) Vol. 28, Iss. 5, pp. 425-432
Closed Access | Times Cited: 103
Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
Michishige Terasaki, Munenori Hiromura, Yusaku Mori, et al.
PLoS ONE (2015) Vol. 10, Iss. 11, pp. e0143396-e0143396
Open Access | Times Cited: 96
<p>NLRP3 inflammasome promotes diabetes-induced endothelial inflammation and atherosclerosis</p>
Zhaofei Wan, Yan Fan, Xiaojun Liu, et al.
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 1931-1942
Open Access | Times Cited: 70
DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages
Christoph Brenner, Wolfgang-M. Franz, Sarah Kühlenthal, et al.
International Journal of Cardiology (2015) Vol. 199, pp. 163-169
Closed Access | Times Cited: 69
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Michael Razavi, Yingying Wei, Xiaoquan Rao, et al.
Military Medical Research (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 31
Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation
Taichi Ikedo, Manabu Minami, Hiroharu Kataoka, et al.
Journal of the American Heart Association (2017) Vol. 6, Iss. 6
Open Access | Times Cited: 60
Vildagliptin Stimulates Endothelial Cell Network Formation and Ischemia-induced Revascularization via an Endothelial Nitric-oxide Synthase-dependent Mechanism
Masakazu Ishii, Rei Shibata, Kazuhisa Kondo, et al.
Journal of Biological Chemistry (2014) Vol. 289, Iss. 39, pp. 27235-27245
Open Access | Times Cited: 56
Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice
Hotimah Masdan Salim, Daiju Fukuda, Yasutomi Higashikuni, et al.
Vascular Pharmacology (2015) Vol. 79, pp. 16-23
Closed Access | Times Cited: 53
Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypepide, and dipeptidyl peptidase‐4 inhibitors in experimental animals
Tsutomu Hirano, Yusaku Mori
Journal of Diabetes Investigation (2016) Vol. 7, Iss. S1, pp. 80-86
Open Access | Times Cited: 49
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Yusaku Mori, Takanori Matsui, Tsutomu Hirano, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1509-1509
Open Access | Times Cited: 40
DPP4 Activity, Hyperinsulinemia, and Atherosclerosis
Kaitlin M. Love, Zhenqi Liu
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 106, Iss. 6, pp. 1553-1565
Open Access | Times Cited: 36
Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
Roger Yazbeck, Simone Jaenisch, Catherine A. Abbott
Biochemical Pharmacology (2021) Vol. 188, pp. 114517-114517
Open Access | Times Cited: 36
Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice
Hotimah Masdan Salim, Daiju Fukuda, Yasutomi Higashikuni, et al.
Vascular Pharmacology (2017) Vol. 96-98, pp. 19-25
Closed Access | Times Cited: 45
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Daiji Kawanami, Keiichiro Matoba, Kazunori Sango, et al.
International Journal of Molecular Sciences (2016) Vol. 17, Iss. 8, pp. 1223-1223
Open Access | Times Cited: 42
The protective role of DPP4 inhibitors in atherosclerosis
Hengdao Liu, Lingli Guo, Junhui Xing, et al.
European Journal of Pharmacology (2020) Vol. 875, pp. 173037-173037
Closed Access | Times Cited: 38
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Michał Wiciński, Karol Górski, Eryk Wódkiewicz, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2275-2275
Open Access | Times Cited: 33
Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches
Suvi E. Heinonen, Guillem Genové, Eva Bengtsson, et al.
Journal of Diabetes Research (2015) Vol. 2015, pp. 1-14
Open Access | Times Cited: 39
The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice
Yannick Waumans, Gwendolyn Vliegen, L. Maes, et al.
Inflammation (2015) Vol. 39, Iss. 1, pp. 413-424
Open Access | Times Cited: 38
Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet
Meng Zhang, Hongting Zhao, Jing Cai, et al.
PLoS ONE (2017) Vol. 12, Iss. 9, pp. e0185688-e0185688
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top